Aquestive Therapeutics (AQST) vs Evolus (EOLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Evolus (EOLS) has outperformed Aquestive Therapeutics (AQST) over the past year, gaining 23.6% versus a loss of 22.6%. Over five years, AQST leads with a +19.4% price change compared with +0.9% for EOLS. Aquestive Therapeutics is the larger company by market cap ($581.7 million vs $502.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AQST | EOLS |
|---|---|---|
| Share price | $4.64 | $7.61 |
| Market cap | $581.75M | $502.31M |
| 1-day change | +0.32% | -1.74% |
| YTD return | -28.48% | +16.39% |
| 1-year return | -22.61% | +23.64% |
| 5-year return | +19.38% | +0.91% |
| Forward P/E | — | 26.00 |
| EPS (TTM) | $-0.66 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.55 | $9.31 |
| 52-week low | $2.93 | $3.86 |
| Distance from 52-week high | -38.61% | -18.31% |
| Analyst consensus | none | none |
| Avg. price target upside | +101.29% | +97.24% |
| Average volume | 2.66M | 896.67K |
| Shares outstanding | 125.51M | 66.05M |
| Employees | 147 | 353 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EOLS has outperformed AQST by 46.3 percentage points over the past year.
About Aquestive Therapeutics
AQST stock →Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Health Care · Biotechnology: Pharmaceutical Preparations · 353 employees
AQST vs EOLS FAQ
Which is bigger, Aquestive Therapeutics or Evolus?
Aquestive Therapeutics (AQST) is larger, with a market capitalization of $581.75M compared with $502.31M for Evolus (EOLS).
Which stock has performed better over the past year, AQST or EOLS?
EOLS returned +23.64% over the past 12 months, compared with -22.61% for AQST (price return, excluding dividends). Past performance does not predict future results.
Are Aquestive Therapeutics and Evolus in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.